Search

Eye testing at home – developing an app for measuring vision

COVID-19 has made home vision monitoring a necessity. Stephanie Campbell shares how her idea for a vision testing app that would engage patients became a reality. Months before COVID-19 first began to mutate to its human host, there was a...

VISION 2020 LINKS Programme and DR-NET World Sight Day Workshop

World Sight Day (WSD) was celebrated globally on 8 October 2020 [1]. From Australia and the Pacific to the Americas, via Asia, Africa and the Caribbean, awareness-raising and advocacy activities took place throughout the day, to focus attention on unnecessary...

The bionic eye – behind the headlines

Multiple visual prosthetic projects and other vision regeneration initiatives being tested in preclinical and clinical development worldwide illustrate continuing progress and opportunities in addressing profound blindness from hereditary retinal diseases and other causes (Table 1). Three implantable bionic vision systems...

Cutting-edge practice in glaucoma care: what, how and why?

More effective treatments and drug delivery modalities, implantable minimally invasive glaucoma surgical (MIGS) devices, as well as accelerating clinical research programmes, will transform the surgical and clinical management of glaucoma in the near future. There is also an ever-greater emphasis...

What’s next in retinal imaging? Faster, deeper and full-on

Fast-evolving technological leaps are opening the way toward clinically useful ocular coherence angiography, generating 3-dimensional microvasculature maps without intravenous dye injection, as well as whole-eye imaging, handheld patient-operated optical coherence tomography (OCT) devices and, for challenging vitreoretinal procedures, integrated intraoperative...

Contemporary glaucoma therapy: spoilt for choice

The goal of glaucoma management is to prevent visual loss and disease progression in the patient’s lifetime through effective lowering of intraocular pressure (IOP), the primary modifiable risk factor in glaucoma. Sustained and consistent IOP reduction is key to halting...

Rare eye diseases: progress continues with authorised orphan medicines and breakthrough technologies

An update on the development of orphan medicines, recent regulatory treatment approvals for rare eye conditions and advances in retinal prosthetic technologies for blinding diseases. The prevalence of a rare disease is based usually on a range of estimates and...

Eye Capacity: clinical need should drive ophthalmic service provision

Almost two million people in the UK suffer sight loss, a number forecast to double over coming decades. Major causes of blindness are age-related macular degeneration (AMD), glaucoma, diabetic retinopathy, cataract and uncorrected refractive error. Prevalence of these sight-threatening conditions...

Code-Free Deep Learning: a step into the future of ophthalmology

A new focus has arisen within the research domain of artificial intelligence (AI) in healthcare called code-free deep learning (CFDL), and recent research demonstrates that ophthalmology is becoming one of the leading specialties in this field. Artificial intelligence (AI) is...

Progress in retinal disease management: Highlights of the Retina Day, RCOphth 2025 Annual Congress

The Retina Day meeting at the Royal College of Ophthalmologists (RCOphth) 2025 Annual Congress in Liverpool was held on 22 May 2025. This report highlights 10 selected topics of interest to subspecialists and general ophthalmologists. Decarbonising anti-VEGF clinics (or making...

See sweet to C-suite: Peter Holland

See also - See sweet to C-suite: Imran Rahman In this three-part conversation series, Co-editor David Lockington speaks with highly influential individuals about their journey to the top, with advice for the next generation of leaders. Part One: David speaks...